Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

hVMAT2: A Target of Individualized Medication for Parkinson's Disease.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics - 1 Jul 2016

Xiong Nian, Li Nuomin, Martin Eden, Yu Jinlong, Li Jie, Liu Jing, Lee David Yue-Wei, Isacson Ole, Vance Jeffery, Qing Hong, Wang Tao, Lin Zhicheng

Abstract excerpt

Vesicular monoamine transporter 2 (VMAT2) is responsible for sequestering cytosolically toxic dopamine into intracellular secretory vesicles. Animal genetic studies have suggested that reduced VMAT2 activity contributes to the genetic etiology of Parkinson's disease (PD), but this role has not been established in humans. Based on human genetic association and meta-analysis, we first confirm the human VMAT2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dopaminergic Neurons
Share to Epigenesis, Genetic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isoflavones

Share to Neuroprotective Agents

Share to Parkinson Disease

Share to Precision Medicine

Share to Up-Regulation

Share to Vesicular Monoamine Transport Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 27137201
DOI: 10.1007/s13311-016-0435-5
PMCID: PMC4965405

Genes

SLC18A2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

hVMAT2: A Target of Individualized Medication for Parkinson's Disease.PMID 27137201Read ↗

Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease.Semantic proximity Read ↗

Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in womenSemantic proximity Read ↗

Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2.Semantic proximity Read ↗

Vesicular monoamine transporter 2 mRNA levels are reduced in platelets from patients with Parkinson's disease.Semantic proximity Read ↗

Plasma urate and risk of Parkinson's disease: A mendelian randomization study.Semantic proximity Read ↗

Association analysis of polymorphisms in VMAT2 and TMEM106B genes for Parkinson's disease, amyotrophic lateral sclerosis and multiple system atrophy.Semantic proximity Read ↗

Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients.Semantic proximity Read ↗

RIT2 polymorphism is associated with Parkinson's disease in a Han Chinese population.Semantic proximity Read ↗

Tricyclic and tetracyclic antidepressants upregulate VMAT2 activity and rescue disease-causing VMAT2 variantsSemantic proximity Read ↗

Variation in the uric acid transporter gene SLC2A9 and its association with AAO of Parkinson's disease.Semantic proximity Read ↗

Genetic variants related to urate and risk of Parkinson's disease.Semantic proximity Read ↗

Association of VMAT2 gene polymorphisms with alcohol dependence.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.